Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;18(1):39-43.
doi: 10.5588/ijtld.13.0307.

Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis

K-W Jo  1 , S-D Lee  1 , W S Kim  1 , D S Kim  1 , T S Shim  1
Affiliations

Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis

K-W Jo et al. Int J Tuberc Lung Dis. 2014 Jan.

Abstract

Setting: A tertiary referral centre in Seoul, South Korea.

Objective: To investigate the effect of moxifloxacin (MFX) susceptibility and later-generation fluoroquinolone (FQ) use on the treatment outcomes of ofloxacin (OFX) resistant multidrug-resistant tuberculosis (MDR-TB).

Design: Of 223 patients diagnosed with MDR-TB between January 2006 and December 2012, 70 (31.4%) patients with OFX-resistant MDR-TB were enrolled in this retrospective cohort study. Their treatment outcomes were analysed.

Results: The mean age (standard deviation) of the 70 patients was 40.6 (12.9) years; 43 (61.4%) were male and 26 (37.1%) had extensively drug-resistant TB. Of the 70 patients, 22 (31.4%) had MFX-susceptible TB, while the remaining 48 (68.6%) were MFX-resistant. The MFX-susceptible and -resistant groups were comparable in terms of baseline characteristics (including age, sex and radiological severity), and respectively 90.9% (20/22) and 70.8% (34/48) were treated with later-generation FQ-containing regimens (P = 0.074; mainly MFX [40/54, 74.1%]). Treatment success was achieved in 72.7% (16/22) of the MFX-susceptible patients and in 41.7% (20/48) of the MFX-resistant patients (P = 0.021). Treatment failure was significantly higher in the MFX-resistant group (41.7% [20/48] vs. 9.1% [2/22]; P = 0.006).

Conclusion: Patients with OFX-resistant MDR-TB had significantly better treatment outcomes when susceptible to MFX. This probably reflects the effect of later-generation FQ treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.
    Chien JY, Chien ST, Chiu WY, Yu CJ, Hsueh PR. Chien JY, et al. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4708-16. doi: 10.1128/AAC.00425-16. Print 2016 Aug. Antimicrob Agents Chemother. 2016. PMID: 27216062 Free PMC article.
  • Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP. Yuen CM, et al. PLoS Med. 2015 Dec 29;12(12):e1001932. doi: 10.1371/journal.pmed.1001932. eCollection 2015 Dec. PLoS Med. 2015. PMID: 26714320 Free PMC article.
  • Map the gap: missing children with drug-resistant tuberculosis.
    Yuen CM, Rodriguez CA, Keshavjee S, Becerra MC. Yuen CM, et al. Public Health Action. 2015 Mar 21;5(1):45-58. doi: 10.5588/pha.14.0100. Public Health Action. 2015. PMID: 26400601 Free PMC article.
  • Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China.
    Liu Q, Yang D, Qiu B, Martinez L, Ji Y, Song H, Li Z, Wang J. Liu Q, et al. PLoS Negl Trop Dis. 2021 Jan 20;15(1):e0009068. doi: 10.1371/journal.pntd.0009068. eCollection 2021 Jan. PLoS Negl Trop Dis. 2021. PMID: 33471794 Free PMC article.
  • Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
    Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC,… See abstract for full author list ➔ Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, et al. Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Lancet. 2018. PMID: 30215381 Free PMC article. Review.
See all "Cited by" articles

MeSH terms

LinkOut - more resources